Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: selumetinib (oral) Clear all
Terminated Phase 1 Interventional Results available

Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)

NCT03833427
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
Selumetinib, Pembrolizumab
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

NCT00600496
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions
AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
4
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

NCT01974349
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib (oral)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

NCT02046850
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib, rifampicin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

NCT00338130
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Santa Monica, California • Aurora, Colorado • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Interventions
Selumetinib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

NCT02093728
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib, itraconazole, fluconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

NCT00936221
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Dacarbazine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

NCT00559949
View directory record Official record
Conditions
Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
Interventions
Laboratory Biomarker Analysis, Selumetinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Tampa, Florida • Chicago, Illinois • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Early Phase 1 Interventional Results available

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

NCT01313039
View directory record Official record
Conditions
Breast Cancer
Interventions
AZ6244
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 2 Interventional

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

NCT00372788
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
AZD6244, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 1, 2026, 8:06 AM EDT
Terminated Phase 3 Interventional Results available

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

NCT01843062
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Selumetinib, Placebo, Radioactive Iodine Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 1, 2026, 8:06 AM EDT
Active, not recruiting Phase 1 Interventional

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

NCT00463814
View directory record Official record
Conditions
Tumor, Cancer
Interventions
AZD6244
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Recruiting Phase 1 Interventional

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

NCT03326310
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Myelofibroses
Interventions
Azacitidine, Selumetinib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Intermittent Selumetinib for Uveal Melanoma

NCT02768766
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Selumetinib, 100mg, Selumetinib, 125mg, Selumetinib, 150mg, Selumetinib, 175mg, Selumetinib, 200mg, Selumetinib, 225mg
Drug
Lead sponsor
Shaheer A. Khan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

A Study of ARRY-142886 in Patients With Advanced Cancer

NCT00085787
View directory record Official record
Conditions
Advanced Cancer
Interventions
ARRY-142886, MEK inhibitor; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Aurora, Colorado • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

NCT01217450
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
selumetinib, cetuximab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Bethesda, Maryland • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

NCT01635023
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD6244 Dosing Period 1, AZD6244 Dosing Period 2, AZD6244 Dosing Period 3, AZD6244 Dosing Period 4
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 1, 2026, 8:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03392246
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib, Selumetinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Completed Phase 1 Interventional

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

NCT01287130
View directory record Official record
Conditions
Colonic Neoplasms, Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer
Interventions
Cetuximab, AZD6244
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 1, 2026, 8:06 AM EDT
Active, not recruiting Phase 2 Interventional

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

NCT02407405
View directory record Official record
Conditions
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)
Interventions
Selumetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 8:06 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 1, 2026, 8:06 AM EDT